Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator

Exclusion Criteria

• •New York Heart Association (NYHA) Class IV heart failure
• •Myocardial infarction, unstable angina, coronary artery bypass graft (CABG) surgery or percutaneous coronary intervention (PCI) within 4 weeks prior to screening or during the screening period before randomization
• •Hemodynamically significant primary obstructive valvular disease
• •History of congenital heart disease
• •Inherited arrhythmia such as Brugada syndrome. Individuals with long QT syndrome Type 3 (LQT-3) or hypertrophic cardiomyopathy (HCM) may be considered.
• •Individuals who are being considered for cardiac transplantation and are on a cardiac transplant list
• •History of seizures or epilepsy
• •Cardiac ablation within 3 months prior to screening or planned cardiac ablation during the study
• •Severe renal impairment
• •Abnormal liver function tests
• •Currently taking Class I and Class III antiarrhythmic drugs; such medications should be discontinued 5 half-lives (or 28 days for chronic use of amiodarone) prior to randomization
• •Currently taking drugs or products that are strong inhibitors or inducers of CYP3A; such medications should be discontinued 5 half-lives prior to randomization
• •Currently taking ranolazine; ranolazine should be discontinued at least 7 days prior to randomization
• •Females who are pregnant or are breastfeeding
• •Individuals with a subcutaneous ICD
• •Body mass index (BMI) ≥ 36 kg/m\^2